Wed, Jul 23, 2014, 12:14 AM EDT - U.S. Markets open in 9 hrs 16 mins

Recent

% | $
Click the to save as a favorite.

SodaStream International Ltd. (SODA) Message Board

biztechnologies 15 posts  |  Last Activity: Jul 15, 2014 10:38 AM Member since: Jan 2, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • biztechnologies by biztechnologies Jul 15, 2014 10:38 AM Flag

    Google Chile and Sativex

    I found many Spanish stories and translated using Google translate, as follows:

    ISP allows import of drug derivative of marijuana for sick lupus

    EFE / The Clinic Online July 14, 2014 Tags: import marijuana, drug

    5
    Comments
    Share on Facebook Share on Twitter

    The Institute of Public Health announced today that allowed entry into the country of a drug derived from marijuana, which will be used by a patient suffering from lupus and breast cancer. This unprecedented event occurs in exceptional shape and includes a prescription supporting its use.

    marijuana

    The Public Health Institute (ISP) today announced that Chile allowed entry into the country of a drug derived from marijuana, which will be used by a patient suffering from lupus and breast cancer.

    The importation of the drug Sativex will be exceptionally from a medical indication supporting its use, but the cost will be funded by the patient Cecilia Hyder, local media reported.

    "For Cecilia Hyder ISP support is part of a process where we move from the point of view of public health, because we are giving the opportunity to provide a palliative solution to the various ailments of a patient who is only in this medicine a relief, "said the agency.

    The ISP has authorized at other times the specific import of this drug, but for various reasons has not materialized.

    In Chile marijuana is not sanctioned, but prohibited its cultivation and marketing, which in practice, becomes illegal.

    However, for some time the government has opened up the possibility of allowing medicinal use more widely and there have been street demonstrations to promote legalization.

    In several countries the "cannabis sativa" is used for the treatment of glaucoma, asthma, cancer, migraine, insomnia, and nausea associated with chemotherapy for cancer, multiple sclerosis, peripheral neuropathies nuisance and other neuromuscular disorders vomiting.

  • biztechnologies by biztechnologies Jul 2, 2014 12:00 PM Flag

    Primary Children’s Hospital In Utah Will Study Epidiolex
    July 2, 2014

    In an open-label observational trial at Primary Children’s hospital, 25 children and teens with treatment-resistant epilepsy who apply to be part of a new drug trial will, will receive Epidiolex, a liquid, purified form of cannabidiol (CBD), a nonpsychoactive chemical in marijuana.

    The primary goal will be to test the tolerability of Epidiolex and the optimal dose of CBD, a chemical shown to have powerful anti-seizure properties in children who have tried whole-plant marijuana extracts.

    Parent activists who pushed for Charlee’s Law — which frees Utahns with epilepsy to import whole-plant CBD extracts from states where #$%$ is legal — have long hoped Primary Children’s would study Epidiolex.

    But the timing of the study poses a challenge for families who are on a waiting list for a highly sought CBD oil made by Colorado Springs growers at the Realm of Caring Foundation.

    Those families will be eligible to apply for a Utah “hemp supplement” registration card starting July 8. But taking the oil could exclude them from participating in Primary Children’s study, which has an unknown start date.

    “It’s a decision point for families, to do this study or try a whole plant extract,” acknowledged Clark.

  • biztechnologies by biztechnologies Jul 2, 2014 11:56 AM Flag

    Study: Marijuana Slows Lou Gehrig's Disease

    New research suggests cannabis-based medicine may allow those afflicted with Lou Gehrig's disease to lead longer, more productive lives.

    Researchers from the Complutense University in Spain published their latest findings in the medical journal CNS Neuroscience & Therapeutics, which details an exploration into the effects of the cannabis-based pharmaceutical, Sativex on the debilitating and deadly wrath of ALS, or Lou Gehrig's disease. The consensus is that Sativex slows the progression of Lou Gehrig's disease in laboratory animals.

    The study, which was conducted by injecting mice in late stages of the disease with a combination of THC and CBD extracts, is consistent with previous studies that have found cannabinoids effective in hindering the evolution of Lou Gehrig's disease. Researchers conclude that while clinical trails are necessary to paint a more accurate portrait of the drug's effectiveness on the disease, they believe their findings "provide support that Sativex (or alternative Sativex-like combinations of phytocannabinoids) may serve as a novel disease-modifying therapy in ALS."

    This discovery could eventually change the fate of the nearly 30,000 Americans currently inflicted with the disease, which destroys the brain and spinal cord, and ultimately leads to paralysis and death.

    There are only six states in the US that allows the use of #$%$ for patients suffering from Lou Gehrig's disease: Arizona, Florida, Maine, Michigan, New Jersey and New Mexico. Because the federal government is working with Sativex manufacturer, GW Pharmaceuticals, there is a distinct possibility the drug will soon be FDA approved for clinical trials for ALS and many other serious conditions.

    After all, Sativex is currently being tested in America as a treatment for cancer and epilepsy patients, which is interesting considering marijuana continues to be unrecognized by t

  • biztechnologies biztechnologies Jun 30, 2014 9:21 AM Flag

    where is best place to see the most updated short interest?

  • biztechnologies biztechnologies Jun 20, 2014 9:27 AM Flag

    The FDA has additional motivation to approve because states are doing their own approvals and the feds do not like losing control to the states.

    This substance is very important so it is likely the sooner FDA approves the more likely they are to maintain control..and shape the direction of how marijuana is used in medication

    GW seems to be the best friend of the FDA... and no pharma company in the USA an even research marijuana as a medication because it is labeled schedule 1.

    Not to mention, states like New York and Georgia have already created direct partnerships with GW...

  • biztechnologies by biztechnologies Jun 19, 2014 4:53 PM Flag

    The FDA is likely not thrilled with states doing their own approvals of marijuana based drugs.
    I seriously doubt the FDA wants to lose control of this important substance.

    I think the FDA approves sooner rather than later for selfish reasons...

  • biztechnologies by biztechnologies Jun 19, 2014 9:52 AM Flag

    where can you find the most updated data about GWPH short counts?

  • Reply to

    Sativex success in New Zealand

    by biztechnologies May 12, 2014 2:27 PM
    biztechnologies biztechnologies May 12, 2014 2:55 PM Flag

    yes, i wondered also why Epidiolex was not used???

  • biztechnologies by biztechnologies May 12, 2014 2:27 PM Flag

    google :galliens sativex and look at the Facebook page for Sunday TVNZ. This is a news station that did a story on a child in bad shape because of epilepsy - the news station posted an update yesterday that child is doing so much better becaue of Sativex - this stuff works

  • Product performance

    Almirall said its “platforms of growth” - aclidinium, linaclotide, the cannaboid drug Sativex and the dermatology franchise - increased by 59% and now represent 43% of total sales (versus 32% in first-quarter 2013).

    Revenues from chronic obstructive pulmonary disease (COPD) drug Eklira (aclidinium bromide), the best-selling product at Almirall, have grown 55.2% to 31.2 million euros, representing 15% of our total sales. Eklira’s growth is leading the expansion of the firm’s respiratory franchise that reached 64.5 million euros (+16.8%). Throughout 2014 the company plans to bring Eklirato patients and physicians in 15 new countries.

    Constella (linaclotide), for the treatment of irritable bowel syndrome with constipation, is gaining access to patients and prescribers across Europe. Launched in Italy in first-quarter 2014, it has also been recently approved in Mexico (under the brand Linzess) and Spain where launches are planned in the second and third quarter, respectively. Once these launches are effective, Almirall said it will be commercializing Constella in 12 countries.

    Sativex, for the spasticity in multiple sclerosis indication, is now available through Almirall in 10 European countries. As of the end of first-quarter 2014, Sativex growth in volume was 58% vs the same period of last year. The newsflow in the rest of 2014 will be driven by two new country launches and top line results for a second indication (oncological pain) will read out at year’s end.

  • Reply to

    Iowa Legalizes Cannabis Oil for Epilepsy

    by bryska May 1, 2014 3:15 PM
    biztechnologies biztechnologies May 1, 2014 3:26 PM Flag

    Is Cannabis Oil being legal good or bad for GWPH - is it better for GWPH if only Epidolex legal and not just cannabis oil???

  • Lots of credibility just landed in the lap of home carbonation and SODA the clear leader.

    I think the coming weeks will be very good for SODA - with more partnerships likely announced on earnings call.

  • biztechnologies by biztechnologies Apr 29, 2014 10:35 AM Flag

    You know the time must be close...

  • Reply to

    cramer just gave it a pump

    by irish_farmer Apr 29, 2014 9:58 AM
    biztechnologies biztechnologies Apr 29, 2014 10:07 AM Flag

    what did he say?

  • biztechnologies by biztechnologies Apr 29, 2014 10:04 AM Flag

    Can anyone tell me what Cramer said or a link to where i can red it?

SODA
29.60+0.46(+1.58%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.